Japanese Circulation Society
The larger of the two studies (METAOD006), which included over 500 subjects at up to 1mg/daily AOD-9604, reported the following side effects: Any adverse event: 78.7% vs
There have been several head-to-head clinical trials comparing the efficacy of different GLP-1 receptor agonists broadly demonstrating the superiority of semaglutide to comparators [37]
however, events such as nausea, vomiting, lethargy, sinus tachycardia, respiratory depression, bradycardia, hypotension, hypertension, sedation, somnolence, mydriasis, stupor, hypothermia, drooling, and coma have occurred